This study evaluated CERE-110 gene therapy in people with mild to moderate Alzheimer's disease. The treatment delivers the nerve growth factor gene into the brain surgically using an adeno-associated virus (AAV) vector, and was compared against placebo surgery. It was carried out as a Phase 2 study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Diagnosis of mild to moderate Alzheimer's disease * Approved medications for Alzheimer's disease may be taken if the dose has been stable for 3 months * A study partner who can attend all study visits * Good general health * Medically able to undergo neurosurgery Exclusion Criteria: * Significant neurological disease other than Alzheimer's disease * Significant depression or other psychiatric disorder * Unstable medical conditions